Bristol-Myers Squibb (BMY) Tops Q3 EPS by 17c, Beats on Revenue, Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $60.86 -1.33%
Revenue Growth %: +4.3%
Financial Fact:
Net Earnings: 1.22B
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +4.3%
Financial Fact:
Net Earnings: 1.22B
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $1.99, $0.17 better than the analyst estimate of $1.82. Revenue for the quarter came in at $11.22 billion versus the consensus estimate of $11.15 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2022 revenue of $46 billion, versus the consensus of $46 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Danaher (DHR) Tops Q3 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance
- UDR raises 2026 full-year guidance, reports Q3 preliminary results
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
